To connect or not to connect?
To connect, or not to connect? That is the question – when should a medical device go digital? In this presentation and poster, Paul Greenhalgh, Director of Design at Team, covers the questions you should consider before deciding to make your device connected.
Inhaler for users with limited manual dexterity
Vectura had created a concept for a multi-use, single unit dose inhaler that could be ‘pre-loaded’ and stored with a drug blister; this allowed the device to be ready for use by patients with limited manual dexterity. Vectura selected Team Consulting to help progress the development and detailed engineering of the final device.
We carried out an early technical analysis and detailed risk assessments (FMEA) of the device concept. These evaluations revealed opportunities for improvements in three areas: usability, performance and robustness. We worked with Vectura and drew on our core areas of expertise in human factors, industrial design and engineering to improve the design while preserving the original concept. Read more here.
Using data to guide inhaler development
The use of data to guide and inform the development of a novel dry powder inhaler by Chris Hurlstone, Director of Engineering at Team and Phil Swanbury, Director of Device Development at Vectura. In this presentation and poster, Chris and Phil discuss what happens during an inhaler development when inputs don’t come in a straight line.
Actegy came to Team to design a Class I medical device that would help people with breathing and respiratory difficulties. It was predominantly aimed at people suffering with conditions such as asthma, cystic fibrosis, chronic obstructive pulmonary disease (COPD), coronary heart disease and chronic heart failure.
It would also assist with the clearing of mucus from the throat or lungs, particularly for patients with cystic fibrosis, bronchiectasis and COPD. Read more here.
Understanding inhaler use error
All inhalation devices present the opportunity for use error. Understanding the potential for use errors with different inhalers, and the
possible consequences on the delivered lung dose, allows a common industry baseline for use-related risk assessment, human factors
programs and regulatory engagement.
When Mundipharma came to Team Consulting they already had a developed product, manufacturable from low volume production systems. They required a new device design partner, to be responsible for the device constituent part of their product during the process of industrialisation, scale-up and launch.
For this project Team provided an experienced team of mechanical and production engineers, as well as experts in device testing and verification. Read more.
Creating a consistent brand experience
Over the past few years, many pharma companies have chosen to deliver their therapies through ‘off-the-shelf’ platform devices rather than developing their own technology from the ground up. This approach offers huge savings in development costs, timescales, and can reduce risk dramatically; but we are often asked the same questions about what we can do to improve the products.
How can we help make the product stand out from other brands who may be using the same platform? How can we make it feel like it’s from the same family as other products within our brand? How can we ensure we deliver a premium brand experience when we are so restricted in what we can change? Read more here.
Inhaler platform usability
We were approached by a top 20 global pharma company for HF support on a combination product development. Our team guided the client through a comprehensive programme of HFE, from initial analysis and formative testing and IFU development, to validation, reporting and successful submission to the FDA.
The foundation of our client’s HFE programme was a thorough and thoughtful analysis of the tasks, user interface, opportunities for use error and use-related risks associated with the product. Read more.
Read our articles
Respiratory drug delivery: then, now and soon
by Brennan Miles, published in the latest issue of OnDrugDelivery. A look at how the industry has changed in recent decades and what its future might look like, covering topics such as sustainability, device regulation and formulation milestones.
Beyond the inhaler by Nia Stevens. What happens to drug particles or droplets once they enter patient airways? How can we understand this better? How can we judge what’s important for the patient in device development?
First across the line: the great generics race by Brennan Miles. In motor racing the 1980’s became known as the turbo-era. A period where a generation of super-fast, flame spitting, colourful race cars were born. But why the sudden change?
The role of colour in medical devices: a designer’s perspective by Paul Greenhalgh. Colour is a powerful tool we can use when designing medical devices but not all colours are physically achievable.
In our new Regulatory Handbook you will find some tips, guidance and case studies, from people at Team and friends in the industry. Just click here to sign-up, type in your address and we’ll send you a copy in the post as soon as we are all back in the office!